From: Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
All (n = 49), n (%) | Good (n = 27), n (%) | Poor (n = 22), n (%) | |||||||
---|---|---|---|---|---|---|---|---|---|
All | G 1/2 | ≥G 3 | All | G 1/2 | ≥G 3 | All | G 1/2 | ≥G 3 | |
Fatigue | 4 (8) | 4 (8) | 0 | 2 (7) | 2 (7) | 0 | 2 (9) | 2 (9) | 0 |
Pruritis | 3 (6) | 3 (6) | 0 | 3 (11) | 3 (11) | 0 | 0 | 0 | 0 |
Diarrhoea | 6 (12) | 3 (6) | 3 (6) | 2 (7) | 0 | 2 (7) | 4 (18) | 3 (14) | 1 (5) |
Anorexia | 2 (4) | 2 (4) | 0 | 1 (4) | 1 (4) | 0 | 1 (5) | 1 (5) | 0 |
Hypothyroidism | 2 (4) | 2 (4) | 0 | 1 (4) | 1 (4) | 0 | 1 (5) | 1 (5) | 0 |
Rash | 3 (6) | 2 (4) | 1 (2) | 3 (11) | 2 (7) | 1 (4) | 0 | 0 | 0 |
Hyperglycaemia | 1 (2) | 0 | 1 (2) | 1 (4) | 0 | 1 (4) | 0 | 0 | 0 |
Liver dysfunction | 1 (2) | 1 (2) | 0 | 0 | 0 | 0 | 1 (5) | 1 (5) | 0 |
Adrenal insufficiency | 2 (4) | 2 (4) | 0 | 2 (7) | 2 (7) | 0 | 0 | 0 | 0 |
Stomatitis | 1 (2) | 1 (2) | 0 | 1 (4) | 1 (4) | 0 | 0 | 0 | 0 |
Fever | 1 (2) | 1 (2) | 0 | 1 (4) | 1 (4) | 0 | 0 | 0 | 0 |